Spero Therapeutics

$16.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.72 (+4.74%) Today
+$0.10 (+0.63%) As of 10:15 PM UTC after-hours

Why Robinhood?

You can buy or sell SPRO and other stocks, options, and ETFs commission-free!

About SPRO

Spero Therapeutics, Inc. Common Stock, also called Spero Therapeutics, is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA. The listed name for SPRO is Spero Therapeutics, Inc. Common Stock.

CEO
Ankit A. Mahadevia
Employees
57
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
432.43M
Price-Earnings Ratio
Dividend Yield
Average Volume
284.60K
High Today
$16.86
Low Today
$15.67
Open Price
$15.86
Volume
345.88K
52 Week High
$16.86
52 Week Low
$5.25

Collections

SPRO Earnings

-$1.32
-$0.88
-$0.44
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 16, After Hours

You May Also Like